Say goodbye to dry eye disease.
The U.S. Food and Drug Administration has approved Tryptyr (acoltremon ophthalmic solution), a new treatment for dry eye disease. This medication is the first of its kind to act on the TRPM8 receptor, helping to relieve symptoms by stimulating nerves in the cornea that boost natural tear production. The solution will be offered in single-use vials, with a recommended dosage of one drop in each eye twice a day.
Dry eye disease has long posed challenges for both patients and physicians due to limited treatment options that often yield slow results and poor adherence. Tryptyr offers a more immediate therapeutic effect, aiming to address the root cause of tear deficiency rather than just managing symptoms. Its mechanism provides quicker relief by enhancing the eye’s natural ability to produce tears.
The drug’s approval is based on results from two phase 3 trials, COMET-2 and COMET-3, which included over 930 participants. Patients using Tryptyr experienced a significant increase in tear production as early as day one, with sustained improvements through day 90. Common side effects were minimal, with the most frequent being mild discomfort at the site of application.
Medical professionals welcomed the new treatment. Dr. Marjan Farid, a professor of ophthalmology, emphasized the need for more effective options for managing dry eye, especially those that tackle tear production directly. Tryptyr offers hope for better symptom control and patient satisfaction.
Alcon, the company behind Tryptyr, plans to launch the product in the U.S. during the third quarter of 2025. This approval marks a step forward in the treatment of dry eye disease, offering a promising alternative for the millions affected by the condition.
Discussion about this post